KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Equity Average (2016 - 2025)

Historic Equity Average for NovoCure (NVCR) over the last 11 years, with Q3 2025 value amounting to $345.4 million.

  • NovoCure's Equity Average fell 439.52% to $345.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $345.4 million, marking a year-over-year decrease of 439.52%. This contributed to the annual value of $361.3 million for FY2024, which is 1007.77% down from last year.
  • NovoCure's Equity Average amounted to $345.4 million in Q3 2025, which was down 439.52% from $355.7 million recorded in Q2 2025.
  • NovoCure's 5-year Equity Average high stood at $443.5 million for Q3 2022, and its period low was $345.4 million during Q3 2025.
  • In the last 5 years, NovoCure's Equity Average had a median value of $404.7 million in 2023 and averaged $396.0 million.
  • As far as peak fluctuations go, NovoCure's Equity Average surged by 8459.64% in 2021, and later crashed by 1734.37% in 2024.
  • Quarter analysis of 5 years shows NovoCure's Equity Average stood at $411.8 million in 2021, then rose by 7.64% to $443.3 million in 2022, then dropped by 14.71% to $378.1 million in 2023, then dropped by 4.66% to $360.5 million in 2024, then fell by 4.19% to $345.4 million in 2025.
  • Its last three reported values are $345.4 million in Q3 2025, $355.7 million for Q2 2025, and $361.1 million during Q1 2025.